Brief: Marker Therapeutics Reports Interim Results Of Its Multitaa-Specific T Cell Therapy In Patients With Pancreatic Adenocarcinoma
29/05/2020 13:09
May 29 (Reuters) - Marker Therapeutics Inc MRKR.O :
* MARKER THERAPEUTICS REPORTS INTERIM RESULTS OF ITS
MULTITAA-SPECIFIC T CELL THERAPY IN PATIENTS WITH PANCREATIC
ADENOCARCINOMA AT THE 2020 AMERICAN SOCIETY OF CLINICAL ONCOLOGY
(ASCO) VIRTUAL ANNUAL MEETING
Source text for Eikon: ID:nPn2qfkjwa
Further company coverage: MRKR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Marker Therapeutics
See all newsBrief: Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer
Marker Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Marker Therapeutics 2025 net loss widens, hurt by decline in grant income
Brief: Marker Therapeutics FY Basic EPS USD -0.79